CDKN2A and prostate cancer: Additionally, abundant hypermethylated TSGs include RASSF10 and SIX3 in kidney cancer and glioblastoma, respectively [38,39]; PTEN, and CDKN2A in melanoma [40,41]; and CDKN2A, TIMPS, and DAPK in prostate cancer [42].